Leading Dermatologist Michael P. Heffernan, M.D. and Renowned Rheumatologist Alisa E. Koch, M.D. Join Lilly Autoimmune Team

Thu Jan 3, 2013 11:07am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130103:nPnDE36058

Drs. Heffernan and Koch reinforce Lilly commitment to supporting autoimmune
pipeline
INDIANAPOLIS, Jan. 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
announced that  Michael P. Heffernan, M.D., a nationally recognized expert in
complex medical dermatology, psoriasis and clinical trials, has joined its
autoimmune team as distinguished medical fellow.  Alisa E. Koch, M.D., a
rheumatologist who has won numerous academic awards for her extensive work in
rheumatoid arthritis, joined as senior medical fellow.

Most recently, Heffernan was in private practice at Central Dermatology in  St.
Louis, and was formerly the chair of the Department of Dermatology at the 
Wright State University  Boonshoft School of Medicine. He is also a past
president and a member of the board of directors of the Medical Dermatology
Society. In this new position at Lilly, he will provide scientific and medical
direction to those molecules in clinical development for the treatment of
psoriasis and other autoimmune dermatological conditions. He will also serve as
a senior medical advisor to Lilly's advocacy and medical education efforts in
these disease states.

Koch recently served in an endowed chair position, the Frederick G.L. Huetwell
and  William D. Robinson, M.D. Professor of Rheumatology, at the  University of
Michigan  Medical School. As senior medical fellow, her key responsibilities are
to advance and support the development, launch and commercialization of the U.S.
autoimmune programs. She will serve as a representative and advocate for the
programs within the rheumatological professional medical community and support
Lilly's overall medical education efforts in these disease states.

"At Lilly, we are committed to making ongoing improvements in the lives of
patients with a broad range of autoimmune diseases, including psoriasis, lupus
and rheumatoid arthritis, and we are very hopeful about the value we might add
in the future," said Eiry Roberts, M.D., vice president of autoimmune product
development at Lilly. "Mike and Alisa have expressed similar commitment to
addressing unmet patient and provider needs in their respective fields of
dermatology and rheumatology. Their expertise, passion and leadership are the
perfect complement to our autoimmune team."

About  Michael P. Heffernan, M.D.
A board-certified dermatologist, Heffernan has been the principal investigator
for more than 80 research studies on disorders of the skin.

Prior to his tenure in private practice, Heffernan held faculty positions at
established academic institutions. At  Washington University  School of
Medicine, he was an assistant and associate professor and director of the
Dermatology Clinical Research Fellowship. He was honored at the university twice
as Dermatology Teacher of the Year. More recently, he served as the chair,
Department of Dermatology, at  Wright State University  Boonshoft School of
Medicine. While there, he was appointed to the board of directors and sat on
both the clinical chairs committee and executive committee.

Among his accomplishments, Heffernan served as a dermatologist in  the United
States  Air Force and the Air Force Reserves. He has authored more than 60
publications and textbook chapters and serves on the editorial boards for
leading industry publications such as the  Journal of the American Academy of
Dermatology  and  Archives of Dermatology.

Heffernan graduated Phi Beta Kappa from the  University of Notre Dame  with a
bachelor's degree in pre-professional studies. He received his M.D. from the 
University of Michigan. He was a dermatology resident at  Stanford University,
where he served as chief resident and started his focus in clinical trials and
complex medical dermatology.

"I want to thank Lilly for giving me the opportunity to help patients all over
the world with life-altering skin diseases find a better quality of life," said
Heffernan.

About  Alisa E. Koch, M.D.
Prior to holding an endowed chair at the  University of Michigan, Dr. Koch held
an endowed professorship, the Gallagher Professor of Arthritis Research, at 
Northwestern University. While there, she was awarded with the  Northwestern
University  Distinguished Faculty Recognition. She also served as the chief of
rheumatology at the Veterans Administration Chicago Health Care System, Lakeside
Division, for 13 years.

Koch's research interests in the field of rheumatoid arthritis have spanned the
length of her career. She is a member of more than 15 professional societies,
including the Association of American Physicians. She has published more than
225 articles in a number of scientific journals, including  Arthritis and
Rheumatism,  Science  and  Nature. For more than a decade, she has been the
managing editor for  Frontiers in Bioscience, while also sitting on a number of
other editorial boards.

A board-certified rheumatologist, Koch is a member of several professional
societies including the American Association for the Advancement of Science and
the American College of Rheumatology. In 2011, she received the  Lee  C. Howley
Sr. Prize of the Arthritis Foundation, one of the most esteemed awards in
research in her field.

Koch attended  Northwestern University Medical School's honors program in
medical education, where she received her bachelor's and M.D. degrees together
in six years. She completed her fellowship in rheumatology at the  Northwestern
University Medical School.

"I'm extremely excited about being at Lilly and look forward to working with
everyone to move novel therapies forward to combat rheumatic diseases," said
Koch.  

About Lilly's Autoimmune Pipeline
Lilly has established its presence in autoimmunity in just a few short years
through internal research and development and partnerships. Lilly currently has
three potential new medicines in clinical development for a variety of
autoimmune conditions, including tabalumab, an anti-BAFF monoclonal antibody,
for rheumatoid arthritis and lupus; ixekizumab, an anti-IL-17 monoclonal
antibody, for psoriasis and psoriatic arthritis; and baricitinib, a janus kinase
(JAK) inhibitor, for rheumatoid arthritis, psoriasis and diabetic nephropathy.

Tabalumab and ixekizumab were discovered in Lilly's research laboratories.
Baricitinib is being developed in partnership with Incyte Corporation.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in  Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at  www.lilly.com.

This press release contains certain forward-looking statements about tabalumab,
ixekizumab and baricitinib as potential treatments for patients with rheumatoid
arthritis and reflects Lilly's current beliefs. However, as with any
pharmaceutical product, there are substantial risks and uncertainties in the
process of development and commercialization. There is no guarantee that future
study results and patient experience will be consistent with study findings to
date or that the product will be commercially successful. For further discussion
of these and other risks and uncertainties, see Lilly's filings with the United
States Securities and Exchange Commission. Lilly undertakes no duty to update
forward-looking statements.

P-LLY

Refer to:Sonja Popp-Stahly, +1 317-655-2993,  spopp-stahly@lilly.com

(Logo:   http://photos.prnewswire.com/prnh/20031219/LLYLOGO)  

SOURCE  Eli Lilly and Company
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.